Dewpoint Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-09-23.
Dewpoint Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on September 23, 2025. The filing reports $77.16M sold. Its industry group is Biotechnology. It names Ameet Nathwani, M.D. (Executive Officer, Director), Srinivas Akkaraju, M.D., Ph.D. (Director), Regina Barzilay, Ph.D. (Director) (SEC Form D/A, September 23, 2025).
Is this your company?
Sell to companies like Dewpoint Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Dewpoint Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Dewpoint Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in September 2025, largest first.
Get an email when Dewpoint Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Dewpoint Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Dewpoint Therapeutics, Inc. →Get the full cited report on Dewpoint Therapeutics, Inc.
What the filing shows about Dewpoint Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dewpoint Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Dewpoint Therapeutics, Inc.'s address as 451 D Street, Suite 104, Boston, MA 02210.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Dewpoint Therapeutics, Inc. →
Amended on 2026-07-13: the offering size changed from $59,124,298 to $82,299,400; the amount sold changed from $59,124,298 to $77,164,102; the number of investors changed from 21 to 23. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Dewpoint Therapeutics, Inc. See pricing
Dewpoint Therapeutics, Inc. is a registered filer with the SEC (CIK 1828893) and has filed since 2025-09-23. 2 filings are on record, the latest on 2026-07-13.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Dewpoint Therapeutics, Inc.'s Form D of 2025-09-23 names Ameet Nathwani, M.D., Srinivas Akkaraju, M.D., Ph.D., Regina Barzilay, Ph.D. and 8 more as its officers, directors or promoters.
Its new offerings report $59.12M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Ameet Nathwani, M.D. is named as Executive Officer and Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Srinivas Akkaraju, M.D., Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Regina Barzilay, Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Olivier Brandicourt, M.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Giuseppe Ciaramella, Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Anthony Hyman, Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Mark Murcko, Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Amir Nashat, Sc.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Steven Neier, Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Richard Young, Ph.D. is named as Director on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
Isaac Klein, M.D., Ph.D. is named as Executive Officer on the Form D that Dewpoint Therapeutics, Inc. filed with the SEC on 23 September 2025, one of 11 people that filing names.
11 people named on the filing — 2 holding an executive role and 9 as directors only.
Named as of the 2025-09-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Dewpoint Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dewpoint Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dewpoint Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Dewpoint Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Dewpoint Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Dewpoint Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/dewpoint-therapeutics-inc-form-d-25000001